

#3



1

SEQUENCE LISTING

<110> Reiter , Yoram  
Denkberg, Galit

<120> ANTIBODY HAVING A T-CELL RECEPTOR-LIKE SPECIFICITY, YET HIGHER  
AFFINITY, AND THE USE OF SAME IN THE DETECTION AND TREATMENT OF CANCER, VIRAL  
INFECTION AND AUTOIMMUNE DISEASE

<130> 01/23094

<160> 11

<170> PatentIn version 3.1

<210> 1

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, gp100 (154)

<400> 1

Lys Thr Trp Gly Gln Tyr Trp Gln Val  
1 5

<210> 2

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, gp100 (209)

<400> 2

Ile Met Asp Gln Val Pro Phe Ser Val

1                      5

<210> 3

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, gp100 (280)

<400> 3

Tyr Leu Glu Pro Gly Pro Val Thr Val  
1                      5

<210> 4

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, MUC1

<400> 4

Leu Leu Leu Thr Val Leu Thr Val Leu  
1                      5

<210> 5

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, HTLV-1 (TAX)

<400> 5

Leu Leu Phe Gly Tyr Pro Val Tyr Val  
1                      5

<210> 6

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, hTEroom temperature (540)

<400> 6

Ile Leu Ala Lys Phe Leu His Trp Leu  
1 5

<210> 7

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, hTEroom temperature (865)

<400> 7

Arg Leu Val Asp Asp Phe Leu Leu Val  
1 5

<210> 8

<211> 711

<212> DNA

<213> Artificial sequence

<220>

<223> G1 Single chain Fv-recombinant antibody DNA sequence

<400> 8

cagggtgaaac tgcaggagtc tgggggaggc ttagtgaagc ctggagggtc cctgaaactc	60
tcctgtgcag cctctggatt cactttcagt agctatggca tgtcttgggt tgcgcagact	120
ccagacaaga ggctggagtg ggtcgcaacc attagtagtg gtggtagtta cacctactat	180
ccagacagtg tgaaggggcg attcaccatc tccagagaca atgccaagaa caccctgtac	240
ctgcaaatga gcagtctgaa gtctgaggac acagccatgt attactgtgc aagaggtaac	300
tgggaaggat ggtacttcga tgtctggggc caagggacca cggtcaccgt ctctcaggt	360

```

ggaggcgggt caggcggagg tggctctggc ggtggcggat cgaacatcga gctcactcag 420
tctccagcaa tcatgtctgc atctccaggg gagagggtca ccatgacctg cagtgccagc 480
tcaagtatac gttacatata ttggtaccaa cagaagcctg gatcctcccc cagactcctg 540
atttatgaca catccaacgt ggctcctgga gtcccttttc gcttcagtgg cagtgggtct 600
gggacctctt attctctcac aatcaaccga atggaggctg aggatgctgc cacttattac 660
tgccaggagt ggagtgggta tccgtacacg ttcggagggg ggacaaagtt g 711

```

<210> 9

<211> 237

<212> PRT

<213> Artificial sequence

<220>

<223> G1 single chain Fv- recombinant antibody protein sequence

<400> 9

```

Gln Val Lys Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1           5           10           15

```

```

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20           25           30

```

```

Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val
35           40           45

```

```

Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val
50           55           60

```

```

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65           70           75           80

```

```

Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys
85           90           95

```

```

Ala Arg Gly Asn Trp Glu Gly Trp Tyr Phe Asp Val Trp Gly Gln Gly
100           105           110

```

```

Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115           120           125

```

```

Ser Gly Gly Gly Gly Ser Asn Ile Glu Leu Thr Gln Ser Pro Ala Ile
130           135           140

```

Met Ser Ala Ser Pro Gly Glu Arg Val Thr Met Thr Cys Ser Ala Ser  
 145 150 155 160

Ser Ser Ile Arg Tyr Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser  
 165 170 175

Pro Arg Leu Leu Ile Tyr Asp Thr Ser Asn Val Ala Pro Gly Val Pro  
 180 185 190

Phe Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile  
 195 200 205

Asn Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Glu Trp  
 210 215 220

Ser Gly Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu  
 225 230 235

<210> 10

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> Influenza derived HLA-restricted peptide

<400> 10

Gly Ile Leu Gly Phe Val Phe Thr Leu  
 1 5

<210> 11

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> Hepatitis B derived HLA-restricted peptide

<400> 11

Ser Thr Asn Arg Gln Ser Gly Arg Gln  
 1 5